Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that affects women of reproductive age. It is one of the most common endocrine disorders in women and affects approximately 10% of women of reproductive age in the United States. PCOS is characterized by irregular periods, excess androgen production, and polycystic ovaries. The U.S Polycystic Ovary Syndrome Treatment market is expected to witness significant growth in the coming years due to the increasing prevalence of PCOS, the availability of advanced healthcare facilities, and the introduction of novel therapeutics.
Market Size and Growth:
The insulin sensitizing agents drugs class segment is estimated to lead in terms of revenue contribution to the U.S. polycystic ovarian syndrome treatment market and is estimated to account for a little more than 30% market share by the end of 2024. The segment is likely to be valued at over US$ 75 Mn in 2017 and is expected to reach close to US$ 100 Mn by 2024 end. Currently, around 70% of polycystic ovarian syndrome patients are overweight and prone to type 2 diabetes.
Thus, insulin sensitizing agents are the most widely prescribed drugs for polycystic ovarian syndrome treatment. Insulin sensitizing agents drug class segment is expected to reflect a market attractiveness index of 2.0 over the estimated period. The segment is anticipated to create absolute $ opportunity of close to US$ 3 Mn in 2017 over 2016.
Order the sample copy of report @ https://www.persistencemarketresearch.com/samples/14317
The U.S Polycystic Ovary Syndrome Treatment market can be segmented based on therapy type, distribution channel, and geography. Based on therapy type, the market can be further categorized into oral contraceptives, anti-androgens, insulin-sensitizing agents, and others. Oral contraceptives are the most commonly prescribed treatment for PCOS as they help regulate menstrual cycles and reduce androgen production. Anti-androgens such as spironolactone and flutamide are prescribed to reduce androgen production. Insulin-sensitizing agents such as metformin are prescribed to treat insulin resistance in women with PCOS.
Based on the distribution channel, the U.S Polycystic Ovary Syndrome Treatment market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies accounted for the largest market share in 2020 due to the availability of advanced medical facilities and the presence of skilled healthcare professionals.
Geographical Analysis:
The U.S Polycystic Ovary Syndrome Treatment market can be segmented into four regions: West, South, Midwest, and Northeast. The South accounted for the largest market share in 2020 due to the high prevalence of PCOS in the region. The Midwest region is expected to witness the highest CAGR during the forecast period due to the increasing awareness about PCOS and the rise in healthcare expenditure.
Key Players:
The key players operating in the U.S Polycystic Ovary Syndrome Treatment market include Bayer AG, Pfizer Inc., Novartis International AG, Ferring Pharmaceuticals Inc., Merck & Co., Inc., Abbott Laboratories, Sanofi, AstraZeneca plc, Eli Lilly and Company, and GlaxoSmithKline plc. These players are investing in research and development activities to introduce novel therapeutics for the treatment of PCOS.
Conclusion:
In conclusion, the U.S Polycystic Ovary Syndrome Treatment market is expected to witness significant growth in the coming years due to the increasing prevalence of PCOS, the availability of advanced healthcare facilities, and the introduction of novel therapeutics. The market can be segmented based on therapy type, distribution channel, and geography. The South accounted for the largest market share in 2020, while the Midwest region is expected to witness the highest CAGR during the forecast period. The key players operating in the market are investing in research and development activities to introduce novel therapeutics for the treatment of PCOS.